Primary infection - Erythema migrans references

Christova I, Komitova R. Clinical and epidemiological features of Lyme borreliosis in Bulgaria. Wien Klin Wochenschr. 2004;116(1-2):42-6. [PubMed]

Hercogová J, Tománková M, Barták P. Contributions to the treatment of dermatologic manifestations of Lyme borreliosis. Cutis. 1992 Jun;49(6):409-11. [PubMed]

Lipsker D, Hansmann Y, Limbach F, Clerc C, Tranchant C, Grunenberger F, Caro- Sampara F, Attali P, Frey M, Kubina M, Piémont Y, Sibilia J, Jaulhac B; GEBLY Study Group. Study Group for Lyme Borreliosis. Disease expression of Lyme borreliosis in northeastern France. Eur J Clin Microbiol Infect Dis. 2001;20(4):225- 30. [PubMed]

Melski JW, Reed KD, Mitchell PD, Barth GD. Primary and secondary erythema migrans in central Wisconsin. Arch Dermatol. 1993;129(6):709-16. [PubMed]

Schmid GP. Epidemiology and clinical similarities of human spirochetal diseases. Rev Infect Dis. 1989;11Suppl 6:S1460-9. Review type. [PubMed

 

 

Some definitions of Terminology

✓  The secondary stage results from the dissemination of Borrelia during the early latent stage.

✓  The late stage is considered chronic if the duration is more than six months.

✓ ** (double red asterisks) indicates possibility of fatality from the condition 

© Copyright 2017. Global Network on Institutional Discrimination and Ad Hoc Committee for Health Equity in ICD11 Borreliosis Codes All Rights Reserved 

Subscribe to the
On-Lyme newsletter